AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

CD40 Agonist - 2019 Pipeline Insight Report: Detailed Therapeutic Product Profiles with Key Coverage of Developmental Activities - ResearchAndMarkets.com

March 21, 2019

DUBLIN--(BUSINESS WIRE)--Mar 21, 2019--The “CD40 Agonist -Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

CD40 Agonist - Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across CD40 Agonist development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Scope of the Report

  • Provides a snapshot of the therapeutics pipeline activity for CD40 Agonist
  • Features the CD40 Agonist pipeline across the complete product development cycle including all clinical and non-clinical stages
  • Offers detailed therapeutic product profiles of CD40 Agonist with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
  • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
  • Coverage of dormant and discontinued pipeline projects across CD40 Agonist

Reasons to Buy

  • Establish a comprehensive understanding of the current pipeline scenario across CD40 Agonist to formulate effective R&D strategies
  • Assess challenges and opportunities that influence CD40 Agonist research & development (R&D)
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Identify and understand the sought after therapy areas and indications for CD40 Agonist
  • Identify the product attributes and use it for target finding, drug repurposing, and precision medicine
  • Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for CD40 Agonist to enhance and expand business potential and scope
  • Plan prospective mergers and acquisitions effectively by identifying key players in this area and their most promising pipeline therapeutics and developmental progress

Companies Mentioned

  • Seattle Genetics
  • Apogenix
  • Alligator Bioscience
  • Celldex Therapeutics Inc.
  • Roche
  • Epitomics
  • Memgen LLC

Key Topics Covered

1. Report Introduction

2. CD40 Agonist - Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for CD40 Agonist

4. Comparative Analysis

5. CD40 Agonist Pipeline Products in Clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

6. CD40 Agonist Pipeline Products in Non-clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment: Active Products

  • Pipeline Assessment by Route of Administration
  • Pipeline Assessment by Stage and Route of Administration
  • Pipeline Assessment by Molecule Type
  • Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

  • Product Description
  • Research and Development
  • Product Development Activities
  • Reason for dormancy/discontinuation

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/p5vg9q/cd40_agonist?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190321005635/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 03/21/2019 01:49 PM/DISC: 03/21/2019 01:49 PM

http://www.businesswire.com/news/home/20190321005635/en